Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA - PubMed (original) (raw)

Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

Aoibhlinn O'Toole et al. Dig Dis Sci. 2016 Jun.

Abstract

Background: Anti-TNF therapies have revolutionized the treatment of autoimmune inflammatory conditions. Paradoxical treatment with these agents is associated with the development of de novo autoimmune diseases. Less well recognized is the provocation of de novo IBD by these agents. Etanercept is not effective for the treatment of inflammatory bowel disease and may be more often reported with the development of Crohn's disease or ulcerative colitis.

Aim: This study assessed the association of new onset IBD in patients with receiving etanercept.

Methods: The Brigham and Women's (BWH) patient database and the FDA Adverse Event Reporting System were searched for cases of IBD reported with etanercept.

Results: A total of 443 cases were identified: 5 pts at BWH (3 CD, 2 UC) and 438 (294 CD, 144 UC) reported to the FDA. Data which were most complete were pooled from 49 patients. NSAID use was reported in 43 % and combination with methotrexate in 29 %. Etanercept was discontinued in 34 pts and 19 required treatment with a different anti-TNF agent. Eight patients had resolution of GI symptoms on discontinuation of etanercept. Therapy was continued in three patients in response to 5-ASA therapy.

Conclusion: Development of IBD should be suspected in patients receiving etanercept who develop GI symptoms. This phenomenon appears more commonly associated with initiation of CD. The clinical phenotype appears indistinguishable from usual patterns of IBD. Unlike other autoimmune phenomenon associated with anti-TNF therapy, IBD often does not resolve when the agent is discontinued. This tentative association requires further investigation.

Keywords: Anti-TNF; Crohn’s disease; Etanercept; FDA; Inflammatory bowel disease; Paradoxical; Ulcerative colitis.

PubMed Disclaimer

Cited by

Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?
Nehring P, Przybyłkowski A. Nehring P, et al. Pharmaceut Med. 2020 Aug;34(4):257-262. doi: 10.1007/s40290-020-00340-1. Pharmaceut Med. 2020. PMID: 32514931 Free PMC article. Review.
Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis.
McGonagle D, Watad A, Sharif K, Bridgewood C. McGonagle D, et al. Front Immunol. 2021 Mar 19;12:614255. doi: 10.3389/fimmu.2021.614255. eCollection 2021. Front Immunol. 2021. PMID: 33815371 Free PMC article. Review.
Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
Park Y, Cheon JH. Park Y, et al. Curr Gastroenterol Rep. 2020 Mar 19;22(5):24. doi: 10.1007/s11894-020-00759-1. Curr Gastroenterol Rep. 2020. PMID: 32193746 Review.
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.
Lopetuso LR, Cuomo C, Mignini I, Gasbarrini A, Papa A. Lopetuso LR, et al. Int J Mol Sci. 2023 May 3;24(9):8187. doi: 10.3390/ijms24098187. Int J Mol Sci. 2023. PMID: 37175894 Free PMC article. Review.
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview.
Rodríguez S, Muñoz A, Bustos RH, Jaimes D. Rodríguez S, et al. Biomedicines. 2020 Aug 23;8(9):303. doi: 10.3390/biomedicines8090303. Biomedicines. 2020. PMID: 32842558 Free PMC article. Review.

References

1. Dermatol Ther. 2014 Jul-Aug;27(4):211-4 - PubMed
1. Proc AMIA Symp. 2002;:552-6 - PubMed
1. Inflamm Bowel Dis. 2008 Jun;14(6):738-43 - PubMed
1. Arthritis Rheum. 2003 Apr;48(4):1093-101 - PubMed
1. Semin Arthritis Rheum. 2009 Dec;39(3):176-81 - PubMed

Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA - PubMed (original) (raw)